‘New Gold Standard’ for Previously Untreated CLL
SAN DIEGO — A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the randomized FLAIR trial indicated. At 3 years, progression-free survival (PFS) rates reached 97% for patients randomized to venetoclax (Venclexta) plus ibrutinib (Imbruvica), as compared with 77% […]